Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

April 22, 2024

https://www.globenewswire.com/news-release/2024/04/22/2867233/36461/en/Voyager-Therapeutics-to-Present-Broad-Set-of-Translational-Data-Supporting-IV-Delivered-CNS-Gene-Therapy-Programs-Advancing-Toward-Clinical-Trials-at-the-ASGCT-27th-Annual-Meeting.html

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene therapy programs across 12 oral and poster presentations at the upcoming American Society of Gene & Cell Therapy’s (ASGCT) 27th annual meeting taking place in Baltimore, May 7-11. The findings span the cross-species and receptor-driven translatability, manufacturability, and overall performance of Voyager’s novel IV-delivered CNS capsids, which are enabling multiple gene therapies to advance towards clinical trials next year.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.